MOTS-c Benefits: What Studies Report

MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a short peptide encoded within mitochondrial DNA rather than nuclear DNA. A 2023 review in Frontiers in Endocrinology described MOTS-c as a mitochondrial-derived peptide being examined for therapeutic exploitation across metabolic and stress-response settings (PMID 36761202). This page organises what published studies have measured and reported by outcome domain, and labels the model used — cell culture, rodent, or human. For background on what the peptide is and how it was discovered, see the overview at /learn/mots-c/.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition or medical decision. Nothing here describes a protocol, and no outcome described below should be read as an expected result in a person.

How to Read the Evidence Base

Almost all of the MOTS-c literature summarised here used animal models, isolated tissue, or cultured cells. That matters because effects reported in a mouse or in a cell line frequently do not reproduce in humans, and because injury models (surgical ischemia, chemically induced diabetes, cartilage damage) are not equivalent to everyday physiology. A 2026 review in Sports Medicine that assessed approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance placed peptides of this class in the category of agents used ahead of adequate human safety and efficacy evidence (PMID 41966639).

Metabolic Outcomes: Glucose and Insulin Resistance

The most frequently cited metabolic finding comes from a 2022 study in Pharmacological Research, in which researchers reported that the mitochondrial-derived peptide MOTS-c relieved hyperglycemia and insulin resistance in gestational diabetes mellitus (PMID 34798268). That work was conducted in a disease model rather than in healthy volunteers, and its endpoints were glycemic and insulin-sensitivity measures specific to the gestational diabetes setting (PMID 34798268).

The broader 2023 review positioned MOTS-c within metabolic regulation generally and framed the peptide as a candidate for therapeutic exploitation rather than an established treatment, which is the language reviewers use when human confirmation is still pending (PMID 36761202). A 2025 report in JHEP Reports examined mitochondrial dysfunction as a characteristic of the multigenerational effects of maternal obesity on metabolic dysfunction-associated steatotic liver disease (MASLD), linking mitochondrial biology to hepatic metabolic outcomes in that experimental context (PMID 40496439).

What this does not show

None of the verified metabolic papers reported weight loss, body-composition change or blood-sugar improvement in healthy adults; the gestational diabetes findings were model-based and disease-specific (PMID 34798268), and the review did not present confirmatory human efficacy data (PMID 36761202).

Skeletal Muscle and Exercise-Related Outcomes

A 2026 study in Free Radical Biology & Medicine reported that MOTS-c improved intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner, identifying those signalling pathways as necessary for the effect the researchers observed (PMID 41520850). The endpoints in that work were bioenergetic measures at the level of the mitochondrion, not athletic outcomes such as sprint time, strength or endurance capacity in people (PMID 41520850).

A separate line of muscle research took a different angle. A 2021 paper in EMBO Molecular Medicine reported that MOTS-c promoted phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice — that is, the peptide was studied as an aid to delivering a gene-targeted therapy, not as a muscle-building agent on its own (PMID 33337582).

On the question of athletic performance specifically, the 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance addressed both safety and efficacy and grouped unapproved peptides as lacking the trial evidence that would support performance claims (PMID 41966639).

Lung Injury and Ischemia-Reperfusion Models

Three verified papers examined MOTS-c in lung injury models. A 2025 study in Redox Biology reported that MOTS-c attenuated lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes, describing a mechanism in which the peptide moved into the nucleus and altered antioxidant gene expression (PMID 40403491).

A 2025 paper in Free Radical Biology & Medicine reported that MOTS-c mimicked remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction, with the vascular barrier as the measured endpoint (PMID 39827923). In a 2025 report in the American Journal of Respiratory Cell and Molecular Biology, researchers described MOTS-c promoting glycolysis via an AMPK-HIF-1α-PFKFB3 pathway to ameliorate cardiopulmonary bypass-induced lung injury (PMID 40035775). All three were injury models tied to surgical or experimental ischemia rather than studies of respiratory function in healthy subjects (PMID 40403491, PMID 40035775).

Cardiac Outcomes in Diabetes Models

A 2026 study in Frontiers in Endocrinology reported that aerobic exercise and MOTS-c attenuated diabetic myocardial fibrosis via inhibition of the THBS1/TGF-β signalling pathway, testing exercise and the peptide in the same experimental framework (PMID 41710402). The measured outcome was fibrotic remodelling of heart tissue in a diabetes model; the study did not report cardiovascular event rates or clinical cardiac endpoints in humans (PMID 41710402).

Joint and Cartilage Outcomes

A 2025 paper in Free Radical Biology & Medicine reported that MOTS-c attenuated mitochondrial dysfunction-induced pyroptosis and cartilage degradation in osteoarthritis through an Nrf2-dependent mechanism, with cartilage integrity and inflammatory cell-death markers as the endpoints (PMID 41043625). This was preclinical work; it did not measure pain, joint function or imaging outcomes in patients with osteoarthritis (PMID 41043625).

Liver and Antiviral Findings

A 2024 study in Gut described a novel function of MOTS-c in mitochondrial remodelling contributing to an antiviral role during hepatitis B virus infection, connecting the peptide's effect on mitochondrial structure to viral replication endpoints in that system (PMID 37788894). Separately, the 2025 JHEP Reports analysis of mitochondrial dysfunction in the multigenerational effects of maternal obesity on MASLD examined hepatic mitochondrial biology in that inherited-risk context (PMID 40496439). Neither report constitutes a treatment trial in people with liver disease (PMID 37788894).

Claimed Benefits With Weak or Absent Evidence

Several outcomes commonly associated with MOTS-c in general discussion are not supported by the papers verified for this page:

• Fat loss or body recomposition in humans — no verified paper reported body-composition endpoints in people; the metabolic findings came from a gestational diabetes model (PMID 34798268).
• Longevity or lifespan extension — no lifespan endpoint appears in the verified set; the 2023 review discussed therapeutic potential rather than demonstrated life-extension (PMID 36761202).
• Endurance or strength gains in trained athletes — the 2026 Sports Medicine review covering athletic performance did not establish efficacy for unapproved peptides in that population (PMID 41966639).
• Cognitive, skin or hair outcomes — no verified paper measured these; the muscle work reported bioenergetic endpoints only (PMID 41520850).

Absence of evidence in this citation set is not evidence that an effect is impossible — it means the question has not been answered by the studies summarised here (PMID 36761202).

Safety and Adverse Events: What Studies Report

The verified paper that addressed safety most directly was the 2026 Sports Medicine review of the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, which framed unapproved peptides as carrying uncertain safety profiles because of the shortage of controlled human data (PMID 41966639). The preclinical mechanistic studies summarised above were designed to test biological pathways and injury endpoints rather than to characterise long-term tolerability, so they do not substitute for human safety data (PMID 40403491, PMID 41043625).

From a regulatory standpoint, MOTS-c is not an approved drug product; material sold under that name is generally labelled for research use only, and research-use-only labelling carries no assurance of identity, purity or sterility for human administration. The 2026 review discussed this gap between peptide availability and regulatory approval in the athletic context (PMID 41966639).

Summary of the Literature

Taken together, the verified studies describe a peptide with reproducible signalling activity in mitochondrial and stress-response pathways — AMPK and PGC-1α in muscle (PMID 41520850), Nrf2 in cartilage (PMID 41043625), and antioxidant gene transcription in lung injury (PMID 40403491) — alongside metabolic findings in a gestational diabetes model (PMID 34798268). What the literature in this set does not yet contain is a controlled human efficacy trial for any of the outcomes people most often associate with the peptide, a gap the 2026 review made explicit for unapproved peptides in sport (PMID 41966639).

References

• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes (Redox Biology, 2025)
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism (Free Radical Biology & Medicine, 2025)
• Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD (JHEP Reports, 2025)
• MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury (American Journal of Respiratory Cell and Molecular Biology, 2025)
• MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner (Free Radical Biology & Medicine, 2026)
• MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice (EMBO Molecular Medicine, 2021)
• MOTS-c mimics remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction (Free Radical Biology & Medicine, 2025)
• Aerobic exercise and MOTS-c attenuate diabetic myocardial fibrosis via inhibition of the THBS1/TGF-β signaling pathway (Frontiers in Endocrinology, 2026)